@article{JTD25497,
author = {Nattachai Srisawat and Kamonwan Tangvoraphonkchai and Nuttha Lumlertgul and Kriang Tungsanga and Somchai Eiam-Ong},
title = {Role of acute kidney injury biomarkers to guide renal replacement therapy initiation, what we learn from EARLY-RRT trial and FST trial?},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {12},
year = {2018},
keywords = {},
abstract = {We wrote this letter to the editor in response to the commentary by Hoste et al., and Meersch et al., on our trial “The effect of early Renal Replacement Therapy guided by plasma Neutrophil Gelatinase Associated Lipocalin on outcome of Acute Kidney Injury: a feasibility study (EARLY-RRT)” trial which was recently published in the J Crit Care (1). In brief, we divided the study into two phases, triage and interventional phase, running subsequently. As a guide for triage to renal replacement therapy (RRT), we measured plasma neutrophil gelatinase associated lipocalin (pNGAL) at the enrollment time. Forty patients with pNGAL ≥400 ng/mL (high pNGAL group) were randomized to ‘early’ or ‘standard’ group. Patients with pNGAL },
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/25497}
}